NicOx ophthalmology strategy back on course after Altacor shrug-off
This article was originally published in Scrip
NicOx has licensed one marketed and two development-stage ocular diagnostic tests from Rapid Pathogen Screening. It is building its own commercial organisation in the US and Europe to market AdenoPlus, RPS's rapid point-of-care diagnostic tear sample-based test for adenoviral conjunctivitis, which is authorised for marketing in the US and EU. The company hopes to acquire or in-license additional ophthalmology products, diagnostic and therapeutic, to market through the same infrastructure in future.